Enanta Pharmaceuticals (ENTA) vs Galectin Therapeutics (GALT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Enanta Pharmaceuticals (ENTA) has outperformed Galectin Therapeutics (GALT) over the past year, gaining 7.1% versus a loss of 23.2%. Over five years, GALT leads with a +8.0% price change compared with -83.1% for ENTA. Galectin Therapeutics is the larger company by market cap ($367.1 million vs $352.4 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ENTA | GALT |
|---|---|---|
| Share price | $12.10 | $3.64 |
| Market cap | $352.42M | $367.09M |
| 1-day change | -2.18% | +0.55% |
| YTD return | -23.27% | -12.50% |
| 1-year return | +7.08% | -23.21% |
| 5-year return | -83.07% | +8.01% |
| EPS (TTM) | $-2.42 | $-0.43 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $17.15 | $7.13 |
| 52-week low | $10.20 | $2.03 |
| Distance from 52-week high | -29.45% | -48.95% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +80.41% | +202.20% |
| Average volume | 228.45K | 385.71K |
| Shares outstanding | 29.13M | 100.85M |
| Employees | 120 | 9 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ENTA has outperformed GALT by 30.3 percentage points over the past year.
About Enanta Pharmaceuticals
ENTA stock →Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; EDP-978 for chronic spontaneous urticaria (CSU); Glecaprevir, antiviral protease inhibitors for the treatment of chronic infection with hepatitis C virus or HCV; and EPS-3903 for the treatment of atopic dermatitis.
Health Care · Biotechnology: Pharmaceutical Preparations · 120 employees
About Galectin Therapeutics
GALT stock →Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in drug development to create new therapies for fibrotic disease and cancer. The company's lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in a Phase 2 clinical study in MASH patients with advanced fibrosis and a second Phase 2b clinical trial in MASH patients with compensated cirrhosis and portal hypertension.
Health Care · Biotechnology: Pharmaceutical Preparations · 9 employees
ENTA vs GALT FAQ
Which is bigger, Enanta Pharmaceuticals or Galectin Therapeutics?
Galectin Therapeutics (GALT) is larger, with a market capitalization of $367.09M compared with $352.42M for Enanta Pharmaceuticals (ENTA).
Which stock has performed better over the past year, ENTA or GALT?
ENTA returned +7.08% over the past 12 months, compared with -23.21% for GALT (price return, excluding dividends). Past performance does not predict future results.
Are Enanta Pharmaceuticals and Galectin Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.